RxDoctor Payments Data

Jimmy Lin, MD

Internal Medicine · San Jose, CANPI 1952328585

Payments from drug & device makers

$8,358in general payments, 2019–2025

Across 378 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Amgen$931
  • Novo Nordisk$805
  • Amarin Pharma, Inc.$641
  • IBSA Pharma Inc.$598
  • Johnson & Johnson$517
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$8,10797%
  • Education$2513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,358 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$172,656
Medicare patients
360
Services billed
1,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$100,547
EliquisApixaban114$93,005
RybelsusSemaglutide45$71,139
JanuviaSitagliptin Phosphate48$59,809
FarxigaDapagliflozin Propanediol48$42,388
VascepaIcosapent Ethyl48$37,730
ProliaDenosumab19$31,224
GlyxambiEmpagliflozin/Linagliptin19$31,015
TradjentaLinagliptin36$30,581
VemlidyTenofovir Alafenamide16$23,193
Repatha SureclickEvolocumab18$19,576
XareltoRivaroxaban16$16,728
MyrbetriqMirabegron11$11,694
Atorvastatin Calcium1,120$11,443
Rosuvastatin Calcium485$7,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$344$162,143170 claims
PfizerEliquis, Paxlovid$467$94,435156 claims
Novo NordiskRybelsus$805$71,13945 claims
MerckJanuvia$156$59,80948 claims
AstraZenecaFarxiga$230$42,38848 claims
AmgenProlia$931$31,22419 claims
GileadVemlidy$1,163$23,19316 claims
Johnson & JohnsonXarelto$517$16,72816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →